Comments
Drug firm Laurus Labs on Friday said the US health regulator has made two observations after the inspection of its Visakhapatnam facility in Andhra Pradesh.
The company has completed the United States Food and Drug Administration (USFDA) inspection of its active pharmaceutical ingredient (API) facilities in Units 1 and 3 at Parawada, Visakhapatnam, with two observations, Laurus Labs said in a filing to the BSE.
The observations are procedural in nature, it added.
“This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection,” Laurus Labs said.
The company, however, did not share any details about the observations made by the regulator.
Shares of Laurus Labs on Friday closed at Rs 338.70 on the BSE, up 0.82 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.